FDA Clears Teleflex's Arrow Midline With Chloragard Technology


October 17, 2016—Teleflex Incorporated announced that it has received US Food and Drug Administration (FDA) 510(k) clearance to market its Arrow Midline with Chloragard technology, an antithrombogenic and antimicrobial peripheral venous catheter. 

According to Teleflex, the device is designed to minimize common midline catheter complications such as catheter intraluminal occlusion, thrombus accumulation, and microbial colonization on the catheter surface for a minimum of 30 days. Additionally, the new midline is also designed for use with high-pressure injection for diagnostic studies.

On October 12, the company announced 510(k) clearance to for the Arrow JACC (jugular axillosubclavian central catheter) with Chloragard technology and the TightTrack tunneler.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.